Great Lakes Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.11M | Sell |
13,839
-1,119
| -7% | -$92.3K | 0.01% | 502 |
|
|
2025
Q4 | $1.28M | Buy |
14,958
+347
| +2% | +$28.5K | 0.01% | 492 |
|
|
2025
Q3 | $1.14M | Buy |
14,611
+321
| +2% | +$25.1K | 0.01% | 516 |
|
|
2025
Q2 | $1.12M | Buy |
+14,290
| New | +$1.07M | 0.01% | 504 |
|
|
2024
Q4 | – | Sell |
-5,085
| Closed | -$336K | – | 847 |
|
|
2024
Q3 | $336K | Sell |
5,085
-273
| -5% | -$19.8K | ﹤0.01% | 713 |
|
|
2024
Q2 | $495K | Sell |
5,358
-2,972
| -36% | -$263K | ﹤0.01% | 658 |
|
|
2024
Q1 | $796K | Sell |
8,330
-5,820
| -41% | -$489K | 0.01% | 565 |
|
|
2023
Q4 | $1.08M | Buy |
14,150
+611
| +5% | +$42.5K | 0.01% | 522 |
|
|
2023
Q3 | $938K | Sell |
13,539
-26,600
| -66% | -$2.14M | 0.01% | 534 |
|
|
2023
Q2 | $3.79M | Buy |
40,139
+7,341
| +22% | +$638K | 0.04% | 382 |
|
|
2023
Q1 | $2.71M | Sell |
32,798
-1,381
| -4% | -$109K | 0.02% | 463 |
|
|
2022
Q4 | $2.55M | Sell |
34,179
-283
| -0.8% | -$21.8K | 0.15% | 241 |
|
|
2022
Q3 | $2.85M | Sell |
34,462
-4,125
| -11% | -$397K | 0.06% | 300 |
|
|
2022
Q2 | $3.67M | Sell |
38,587
-3,019
| -7% | -$313K | 0.07% | 275 |
|
|
2022
Q1 | $4.9M | Sell |
41,606
-2,571
| -6% | -$288K | 0.08% | 245 |
|
|
2021
Q4 | $5.72M | Sell |
44,177
-47,604
| -52% | -$5.55M | 0.09% | 246 |
|
|
2021
Q3 | $10.4M | Buy |
91,781
+27,494
| +43% | +$3.14M | 0.16% | 184 |
|
|
2021
Q2 | $6.66M | Buy |
64,287
+22,064
| +52% | +$2.08M | 0.1% | 237 |
|
|
2021
Q1 | $3.53M | Sell |
42,223
-1,405
| -3% | -$119K | 0.06% | 307 |
|
|
2020
Q4 | $3.98M | Buy |
43,628
+1,739
| +4% | +$144K | 0.07% | 284 |
|
|
2020
Q3 | $3.34M | Sell |
41,889
-770
| -2% | -$60.1K | 0.07% | 286 |
|
|
2020
Q2 | $2.95M | Buy |
42,659
+1,358
| +3% | +$96.5K | 0.07% | 277 |
|
|
2020
Q1 | $2.6M | Buy |
41,301
+4,566
| +12% | +$329K | 0.08% | 266 |
|
|
2019
Q4 | $2.86M | Sell |
36,735
-4,524
| -11% | -$353K | 0.06% | 298 |
|
|
2019
Q3 | $3.02M | Buy |
41,259
+1,161
| +3% | +$81.6K | 0.07% | 294 |
|
|
2019
Q2 | $2.47M | Sell |
40,098
-870
| -2% | -$52.6K | 0.05% | 326 |
|
|
2019
Q1 | $2.61M | Sell |
40,968
-7,989
| -16% | -$456K | 0.06% | 304 |
|
|
2018
Q4 | $2.5M | Sell |
48,957
-63,330
| -56% | -$3.2M | 0.06% | 288 |
|
|
2018
Q3 | $6.52M | Sell |
112,287
-18,000
| -14% | -$880K | 0.14% | 150 |
|
|
2018
Q2 | $6.32M | Buy |
130,287
+44,064
| +51% | +$2.06M | 0.15% | 156 |
|
|
2018
Q1 | $4.01M | Buy |
86,223
+37,425
| +77% | +$1.63M | 0.1% | 212 |
|
|
2017
Q4 | $1.83M | Sell |
48,798
-13,779
| -22% | -$506K | 0.04% | 326 |
|
|
2017
Q3 | $2.28M | Buy |
+62,577
| New | +$2.39M | 0.05% | 282 |
|
|
2016
Q3 | – | Sell |
-22,440
| Closed | -$746K | – | 566 |
|
|
2016
Q2 | $746K | Sell |
22,440
-1,020
| -4% | -$34.9K | 0.02% | 391 |
|
|
2016
Q1 | $690K | Buy |
23,460
+5,097
| +28% | +$141K | 0.02% | 400 |
|
|
2015
Q4 | $483K | Buy |
+18,363
| New | +$477K | 0.01% | 424 |
|
|
2014
Q4 | – | Sell |
-25,932
| Closed | -$441K | – | 527 |
|
|
2014
Q3 | $441K | Buy |
+25,932
| New | +$409K | 0.01% | 421 |
|
Other funds holding EW
VCM
VPM
Great Lakes Advisors's EW Position: Q1 2026 in Review
Great Lakes Advisors reduced its Edwards Lifesciences (EW) stake by 7.5% in Q1 2026, selling an estimated $92.3K and leaving 13,839 shares worth $1.11M. The position accounts for 0.01% of the portfolio, ranked #502.
Great Lakes Advisors first reported a position in EW in Q3 2014 and has held it in 37 quarters since. The position peaked at $10.4M in Q3 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Great Lakes Advisors held 13,839 shares of Edwards Lifesciences worth $1.11M as of Q1 2026.
- Great Lakes Advisors sold 1,119 Edwards Lifesciences shares in Q1 2026, an estimated $92.3K.
- Edwards Lifesciences made up 0.01% of Great Lakes Advisors's portfolio in Q1 2026, its #502 holding.
- Great Lakes Advisors first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 37 quarters since.
- Great Lakes Advisors's Edwards Lifesciences position peaked at $10.4M in Q3 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Great Lakes Advisors's 13F filing for Q1 2026, filed 12 May 2026.